TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05774977

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aviation noise plus white noise 40 dBA (AN+BN40)
Description: The AN + BN40 night will consist of the aviation noise (AN) exposure with the addition of continuous pink noise throughout the sleep period at a level of 40 dBA.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aviation noise plus white noise 40 dBA (AN+BN40)
Description: The AN + BN40 night will consist of the aviation noise (AN) exposure with the addition of continuous pink noise throughout the sleep period at a level of 40 dBA.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aviation noise plus white noise 50 dBA (AN+BN50)
Description: The AN + BN50 night will consist of the aviation noise (AN) exposure with the addition of continuous pink noise throughout the sleep period at a level of 50 dBA.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aviation noise plus white noise 50 dBA (AN+BN50)
Description: The AN + BN50 night will consist of the aviation noise (AN) exposure with the addition of continuous pink noise throughout the sleep period at a level of 50 dBA.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aviation noise plus white noise 50 dBA (AN+BN50)
Description: The AN + BN50 night will consist of the aviation noise (AN) exposure with the addition of continuous pink noise throughout the sleep period at a level of 50 dBA.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aviation noise plus white noise 50 dBA (AN+BN50)
Description: The AN + BN50 night will consist of the aviation noise (AN) exposure with the addition of continuous pink noise throughout the sleep period at a level of 50 dBA.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aviation noise plus white noise 50 dBA (AN+BN50)
Description: The AN + BN50 night will consist of the aviation noise (AN) exposure with the addition of continuous pink noise throughout the sleep period at a level of 50 dBA.
Study: NCT06698159

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryoablation with cryoballoon 31 mm
Description: Pulmonary vein isolation using 31 mm balloon cryoablation
Study: NCT06697158

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy and rehabilitation
Description: Complex Decongestive Physiotherapy (CDP) Complex Decongestive Physiotherapy (CDP) consists of Manual Lymphatic Drainage (MLD), skin care, compression bandaging, and exercise, which are routinely used in clinical practice (9). CDP sessions will last approximately one hour each and will be administered for 4 weeks, with 5 sessions per week, totaling 20 sessions.~Manual Lymphatic Drainage (MLD) is a massage technique involving rhythmic, gentle pressure movements aimed at reducing the accumulation of lymphatic fluid in conditions such as lymphedema. This therapy facilitates the drainage of lymphatic fluid into the body's primary lymphatic pathways, thereby reducing edema, pain, and tightness, while enhancing range of motion and overall quality of life. MLD typically focuses on areas with a high concentration of lymph nodes, promoting the smooth circulation of lymph fluid. Treatment sessions usually last between 30 minutes to one hour.
Study: NCT06697951

Intervention type: DEVICE
Group type: OTHER
Intervention: bilevel ventilation with the Neovent
Description: Newborn infants with respiratory distress will be placed on the Neovent and we will see if study staff set up, use, and trouble shoot the Neovent correctly and see if study staff can monitor for safety problems in lower-resourced nurseries and to determine if the infants have any more problems than seen with bubble CPAP or Neovent in a higher resourced nursery including any more nasal irritation, abdominal distention, or clinically important amount of air around the lung (pneumothorax)
Study: NCT06697834

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Histotripsy ultrasound session
Description: The study will be performed with the MINDRAY DP-10 ultrasound device equipped with a linear probe and histotripsy functionality.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VAS questionnaire
Description: Pain assessment with the EVA questionnaire

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AOFAS questionnaire
Description: AOFAS questionnaire at visit 1 and visit 4 (75 days after the first visit).
Study: NCT04811651

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord-derived Mesenchymal Stem Cells
Description: umbilical cord derived mesenchymal stem cells were intravenously injected in a single dose of one hundred million.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intravenous placebo solution with the same appearance as the treatment group.
Study: NCT05774977

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aviation noise plus white noise 50 dBA (AN+BN50)
Description: The AN + BN50 night will consist of the aviation noise (AN) exposure with the addition of continuous pink noise throughout the sleep period at a level of 50 dBA.
Study: NCT06536049

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration and biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow aspiration and biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT and PET/CT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study: NCT03104569

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injection of 37℃ contrast agent
Description: Nonionic contrast agent is heated to 37℃ in a incubator when injection of contrast agent
Study: NCT05774977

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Night (CTRL)
Description: Control night (CTRL) without noise exposure and without earplugs.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Night (CTRL)
Description: Control night (CTRL) without noise exposure and without earplugs.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Night (CTRL)
Description: Control night (CTRL) without noise exposure and without earplugs.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Night (CTRL)
Description: Control night (CTRL) without noise exposure and without earplugs.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Night (CTRL)
Description: Control night (CTRL) without noise exposure and without earplugs.
Study: NCT04880876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25mg Eluxadoline
Description: Oral Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25mg Eluxadoline
Description: Oral Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25mg Eluxadoline
Description: Oral Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25mg Eluxadoline
Description: Oral Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25mg Eluxadoline
Description: Oral Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25mg Eluxadoline
Description: Oral Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25mg Eluxadoline
Description: Oral Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100mg Eluxadoline
Description: Oral Tablets
Study: NCT05774977

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Night (CTRL)
Description: Control night (CTRL) without noise exposure and without earplugs.
Study: NCT05552157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remternetug (SC)
Description: Administered subcutaneously every 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remternetug (SC)
Description: Administered subcutaneously every 12 weeks
Study: NCT06447441

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Enteral supplementation of placebo in 3 consecutive days within 96 hours after ICU admission.
Study: NCT05552157

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo (Remternetug)
Description: Administered as subcutaneous injection of placebo every 12 weeks
Study: NCT06447441

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: Enteral supplementation of 576,000IU/day vitamin D3 in 3 consecutive days within 96 hours after ICU admission
Study: NCT05665361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sasanlimab
Description: Sasanlimab will be given (SC on day 1 of every cycle, starting on day 1 (+/- 5 days) of cycle 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sasanlimab
Description: Sasanlimab will be given (SC on day 1 of every cycle, starting on day 1 (+/- 5 days) of cycle 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbocicilib
Description: Palbociclib will be given PO for 21 days of every 28-day cycle, starting on day 1 of cycle 1.
Study: NCT06428955

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CT LUCIA 621P
Description: The device under investigation, CT LUCIA 621P IOL (Carl Zeiss Meditec, Jena, Germany) is a posterior chamber intraocular lens which is indicated for aphakia after surgical extraction of the cataractous natural lens. It is a monofocal aspheric IOL made of hydrophobic material and coated with heparin. The modified C-loop haptic is step-vaulted.
Study: NCT05665361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbocicilib
Description: Palbociclib will be given PO for 21 days of every 28-day cycle, starting on day 1 of cycle 1.
Study: NCT03963583

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HEROIC
Description: The HEROIC intervention will include individualized, nurse-led sessions focused on;~1. a whole-person assessment including preventive health behaviors, personal goals, and purpose in life~2. discussion of caregiving in the context of the caregiver's identified 'purpose' which supports meaning-making and provides rationale for goal-setting~3. co-development of a plan to address caregiver goals to improve preventive health behaviors and/or reduce caregiver burden~4. 'walking meetings' to model the importance of exercise while discussing incremental action plans to help caregivers achieve goals.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HEROIC
Description: The HEROIC intervention will include individualized, nurse-led sessions focused on;~1. a whole-person assessment including preventive health behaviors, personal goals, and purpose in life~2. discussion of caregiving in the context of the caregiver's identified 'purpose' which supports meaning-making and provides rationale for goal-setting~3. co-development of a plan to address caregiver goals to improve preventive health behaviors and/or reduce caregiver burden~4. 'walking meetings' to model the importance of exercise while discussing incremental action plans to help caregivers achieve goals.
Study: NCT05468138

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SOX
Description: Drug: Tegafur-Gimeracil-Oteracil Potassium The dose of S-1 is according to body-surface area (BSA): patients with a BSA of less than 1.25 m2 received 80 mg daily; those with a BSA of 1.25 m2 or more but less than 1.5 m2 received 100 mg daily; and those with a BSA of 1.5 m2 or more received 120 mg daily. oxaliplatin 130mg/m2, intravenously, on day 1.~Drug: Oxaliplatin The dose of oxaliplatin is according to body-surface area (BSA): 130mg/m2, intravenously, on day 1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XELOX
Description: Drug: Capecitabine 1000mg/m2, orally, twice per day, from day 1 to day 14, Q3W. Drug: Oxaliplatin The dose of oxaliplatin is according to body-surface area (BSA): 130mg/m2, intravenously, on day 1.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observation
Description: follow up and Observation alone. Abdomen/chest CT scan will be performed every 6 months after surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 antibody
Description: Sintilimab at a dose of 200 mg every 3 weeks for 16 cycles or Nivolumab at a dose of 360 mg every 3 weeks for 16 cycles
Study: NCT06293079

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Program
Description: Structured rehabilitation program of the groups; Patient education consists of aerobic and strengthening exercises. An information brochure will be given to patients after the first evaluation about the program to be implemented.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Program
Description: Structured rehabilitation program of the groups; Patient education consists of aerobic and strengthening exercises. An information brochure will be given to patients after the first evaluation about the program to be implemented.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Program
Description: Structured rehabilitation program of the groups; Patient education consists of aerobic and strengthening exercises. An information brochure will be given to patients after the first evaluation about the program to be implemented.
Study: NCT05967065

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: vibration induced nystagmus test
Description: Vibration induced nystagmus test by bone transducer B250.
Study: NCT06075849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PB101
Description: Cohorts of 3-6 patients receive PB101 until the MTD is determined. The dose (2 mg/kg-15 mg/kg) assigned to the cohort will be administered weekly for two 28-day cycles or until progressive disease (PD), unacceptable toxicity, withdrawal of subject consent, and/or the investigator's decision to discontinue the study treatment occurs.~Administration may be continued for subjects in whom PB101 provides clinical benefits at the discretion of the investigator.
Study: NCT06328608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRX-102 1 mg/kg every two weeks
Description: Drug: PRX-102 1 mg/kg every two weeks
Study: NCT06030128

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: core stabilization exercise
Description: All participants will undergo a 16 session exercise program for 2 months. Each session will last for 60minutes. The exercise program will be arranged in a group format with class size ranging from 6-8 per class. Subjects will be divided into experimental and control groups.
Study: NCT04688515

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition program developed using positive deviance approach
Description: It is a 3-month nutrition program including nutrition education session and rehabilitation session. The education session consists of half hour education lesson and one and half hours peer-led cooking session. The cooking demonstration will be led by volunteers from PD family. Participating mothers will need to bring along their children during this session, prepare meal according to pre-planned menu and feed their children with the prepared meal after cooking as snack or additional meal. The rehabilitation session will be the rest of the days following each education session until the next education session. Growth monitoring session will also be conducted in each session, whereby mothers will be taught and trained to weigh their children.
Study: NCT04817514

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shoulder rehabilitation exercises and aerobic exercises
Description: SRG group: the group will only perform mobility and strengthening exercises involving the shoulder complex.~ARG group: The ARG group will perform the shoulder rehabilitation protocol presented above combined with the aerobic exercise program that will last 20 minutes per session at 40% of the reserve heart rate (HRC), progressing up to 40 minutes with a maximum of 60% of the HRC in the last two weeks, according to the recommendations for patients with type 2 DM proposed in the American College of Sports Medicine Guidelines.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shoulder rehabilitation exercises and aerobic exercises
Description: SRG group: the group will only perform mobility and strengthening exercises involving the shoulder complex.~ARG group: The ARG group will perform the shoulder rehabilitation protocol presented above combined with the aerobic exercise program that will last 20 minutes per session at 40% of the reserve heart rate (HRC), progressing up to 40 minutes with a maximum of 60% of the HRC in the last two weeks, according to the recommendations for patients with type 2 DM proposed in the American College of Sports Medicine Guidelines.
Study: NCT05317416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elranatamab
Description: BCMA-CD3 bispecific antibody

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Immunomodulatory drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Immunomodulatory drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elranatamab
Description: BCMA-CD3 bispecific antibody
Study: NCT04670315

Intervention type: DIAGNOSTIC_TEST
Intervention: Telematic evaluation of motor function
Description: Validation of the Telematic Spanish Version of the Fugl Meyer Assessment Scale
Study: NCT06037083

Intervention type: DEVICE
Intervention: Oxygen saturation probe
Description: The high-accuracy oxygen saturation signal will be continuously acquired for 168 hours post extubation from a separate pulse oximeter (Radical-7®, Masimo ROOT platform, MasimoCorp, Irvine, LA).

Intervention type: DEVICE
Intervention: Near infrared spectroscopy sensors
Description: The cerebral and splanchnic regional oxygen saturation signals will be acquired continuously for 168h post extubation using two near infrared spectroscopy sensors (Masimo ROOT platform, MasimoCorp, Irvine, LA), one placed on the forehead for cerebral oxygenation and one on the abdomen (for splanchnic oxygenation).

Intervention type: DEVICE
Intervention: Electrical impedance tomography
Description: The regional lung ventilation will be measured using Electrical Impedance Tomography (TIMPEL, USA) at three time points:~* From 1 hour pre-extubation to 2 hours post extubation (total 3 hours)~* Between 24 and 48 hours post extubation (total 3 hours)~* Between 72 and 96 hours post extubation (total 3 hours)
Study: NCT05685602

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo a tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study: NCT04680780

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Description: Patients will follow a classical ketogenic diet for 3 months
Study: NCT05685602

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo a CT scan

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Emavusertib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo a PET scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo an x-ray
Study: NCT06470451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypericin
Description: HyBryte gel (0.25% hypericin) is applied twice weekly for 18 weeks. Treated lesions are covered with opaque material (such as opaque clothing), followed 21 (±3) hours later by the administration of visible light.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo gel is applied twice weekly for 18 weeks. Treated lesions are covered with opaque material (such as opaque clothing), followed 21 (±3) hours later by the administration of visible light.
Study: NCT05906095

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: LOCK Falls Program
Description: The LOCK Falls Program helps multi-disciplinary frontline staff teams (nursing, physician, housekeeping, physical therapy, etc.) work together to identify and discuss risk factors for falling and use rapid-cycle QI techniques to pilot and monitor their actions to reduce resident falls.
Study: NCT05638477

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Free-viewing eye tracking
Description: Participants will watch 20 minutes of video clips while their eye movements, pupil size and blink rate are recorded

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Free-viewing eye tracking
Description: Participants will watch 20 minutes of video clips while their eye movements, pupil size and blink rate are recorded

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Free-viewing eye tracking
Description: Participants will watch 20 minutes of video clips while their eye movements, pupil size and blink rate are recorded

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Free-viewing eye tracking
Description: Participants will watch 20 minutes of video clips while their eye movements, pupil size and blink rate are recorded
Study: NCT04631302

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Be Mindful
Description: Be mindful is an online course run by the Mental Health Foundation and Wellmind Media. It was developed together with British mindfulness instructors and offers access to its course materials and instructional videos through a website (http://www.bemindfulonline.com).~The course consists of 11 sessions led by two mindfulness teachers, one female, one male. Using a variety of media (videos, assignments, audio tracks and e-mails), participants are taught to use formal as well as informal mindfulness techniques. The course lasts 4 weeks. For each week, participants are asked to do a daily formal mediation practice (up to 30 minutes but it varies from week to week) and one or two informal exercises.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Light exercise course
Description: The control condition involves light physical exercises aimed at increasing mobility, reducing stiffness, improving circulation, and avoiding pain or repetitive strain injuries that may result from sedentary or repetitive tasks common in office environments. The exercises will include simple whole-body slightly aerobic exercises such as rotation of limbs and stretching. The course was developed by Dr Julieta Galante, a public health doctor, together with an expert in body posture re-education and body techniques.~The course is designed to match with the mindfulness intervention condition in duration and media (length of videos, amount of written instructions). It also replicates the encouraged use of short breaks (of seconds or minutes) throughout the workday to focus on wellbeing, as occurs in mindfulness.